MedTrace Logo

Absorption, Metabolism and Excretion Study of [14C]PBT2 and Absolute Bioavailability of PBT2

NCT02249728 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2016-03-30

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to investigate how the test drug, PBT2, is taken up, broken down and removed from the body when given as an oral capsule, a radiolabelled oral suspension and a radiolabelled intravenous injection.

Conditions

  • Healthy Volunteers

Interventions

DRUG

IV PBT2 microtracer and oral PBT2 single dose

DRUG

oral 14C-PBT2

Sponsors & Collaborators

  • Prana Biotechnology Limited

    lead INDUSTRY

Principal Investigators

  • Caroline Herd, PhD · Prana Biotechnology Ltd

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02249728 on ClinicalTrials.gov